The Blavatnik Fund for Innovation at Yale
Please meet all of our Blavatnik Awardees, and watch some of their winning pitch presentations.
Jeffrey Bender, M.D.
TargaCept: An miRNA Target-based Oligonucleotide for the treatment of Uveitis and Other Inflamatory Disorders.
Anton Bennett, Ph.D.
Developing a chemical drug design platform to establish rich intellectual property for a first-in-class therapeutic for the treatment of fibrosis.
Ranjit S. Bindra, M.D., Ph.D.
Athena Therapeutics: Targetting Cancer at its core.
Jonathan Bogan, M.D.
Combatting Obesity through a novel mechanism.
Demetrios Braddock, MD, PhD
Net Therapeutics: Targeting NETs in Human Disease
Elliott Brown, M.D.
A novel bone marrow aspiration device that limits blood contamination and maximizes stem cell recovery.
Sidi Chen, Ph.D.
MAEGI Medicine: New Paradigm of Immune Gene Therapy.
Joseph N. Contessa, MD, PhD
Apira: Developing Therapeutic OST inhibitors
John Deacon Ph.D.
Cytosolics: Targeting Cancer Drugs.
Barbara Ehrlich, Ph.D.
NCS1 - A New Target for Wolfram Syndrome.
Jonathan Ellman, PhD
A novel chemistry approach to target p53 mutation in human cancer. (Co-Pitch with Ya Ha, Ph.D.)
Michael Giradri, M.D., FAAD
A multi-functional bioadhesive nanoparticle platform that has the potential to revolutionize the suncare industry.
Peter M. Glazer, M.D., Ph.D.
Antibody meditated Gene Editing.
Anjelica Gonzalez, PhD
Aero Therapeutics: Preclinical Validation of a Low-Cost Versatile Respirator
Ya Ha, Ph.D.
A novel chemistry approach to target p53 mutation in human cancer. (Co-Pitch with Jonathan Ellman, PhD)
Akiko Iwasaki, Ph.D.
Cynaxis: Immunological Approach to Provide Drug Access to the CNS.
Naftali Kaminski, M.D.
Vittix Therapeutics: Curing Idiopathic Pulmonary Fibrosis with Thyroid Hormone Mimetics.
Mustafa Khokha, MD
Small Molecule Regulation of β-catenin Nuclear Transport: New Targets Against Cancer
Mark A. Lemmon, Ph.D., FRS
Drugging Fibrodysplasia Ossificans Progressiva. (Pitch By Ashtekar, Kumar)
Nikhil Malvankar
Faster, Reliable & Scalable DNA Sequencing using Biomolecular Electronics
Choukri Ben Mamoun, Ph.D.
EliV5: First in class Antifungal Agents.
Virtus Therapeutics: A Novel Therapy for Pantothenate Kinase-Associated Neurodegeneration
Andrew Miranker, Ph.D.
Breaking toxin propagation in multiple system atrophy.
Anna M. Pyle, Ph.D.
Intronistat Therapeutics: Nontoxic Antifungals That Target RNA.
Aaron Ring, M.D., Ph.D.
Breaking the Vicious Cycle of Inflammation and Cell Death in Sepsis.
Engineered Cytokines for Cancer Immunotherapy
Faye Rogers, PhD
TargetGene Therapeutics: Direct Targeting of Amplified Cancer Driver Genes as a Therapeutic Strategy
W. Mark Saltzman, Ph.D.
A multi-functional bioadhesive nanoparticle platform.
Alanna Schepartz, Ph.D.
Cell-Permeable Miniature Proteins: Therapeutic proteins for all.
David Spiegel, M.D., Ph.D., A.B.
MODA Pharmaceuticals: Targeted Elimination Platform for Pathogenic Extracellular Proteins.
Stephen Strittmatter, M.D., Ph.D.
Developing select inhibitors to slow, halt or reverse the course of Alzheimer’s disease.
Andrew Xiao, Ph.D.
Developing therapeutics around a novel epigenetic mechanism aimed at end-stage tumors.